Table 1: Clinical characteristics

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variable  | Missing data from total 20,642 | No EPD Use in PCI (17,730) | EPD use in PCI (2,912) | P-value |
| Median Age (IQR) | 0 | 69 (61-76) | 71 (65-77) | 0.0001 |
| Female sex  | 0 | 3,351/17,730(19%) | 362/2,912(12%) | <0.0001 |
| Smoking  | 2,476 (12%) | 2,418/15,556(16%) | 277/2,610(11%) | <0.0001 |
| Diabetes mellitus  | 779 (4%) | 4,884/17,051(29%) | 925/2,812(33%) | <0.0001 |
| Hypertension  | 1,031 (5%) | 9,825/16,826(58%) | 2,006/2,785(72%) | <0.0001 |
| Hypercholesterolaemia | 1,031(5%) | 9,926/16,826(59%) | 2,056/2,785(74%) | <0.0001 |
| Previous MI | 1,627 (8%) | 8,766/16,453(53%) | 1,714/2,562(67%) | <0.0001 |
| Previous CVA  | 1,031(5%) | 928/16,826(6%) | 231/2,785(8%) | <0.0001 |
| Peripheral vascular disease  | 1,031(5%) | 1,348/16,826(8%) | 387/2,785(14%) | <0.0001 |
| Previous renal disease  | 1,443(7%) | 350/16,497(2.12 %) | 48/2,702(1.78%) | 0.24 |
| Family history of heart disease | 2,846(14%) | 6,835/15,338(45%) | 1,240/2,458(50%) | <0.0001 |
| Indication for PCI |
| STEMI | 0 | 2,118/17,730(12%) | 204/2,912(7%) | <0.0001 |
| UA/NSTEMI | 0 | 7,571/17,730(43%) | 1,711/2,912(59%) | <0.0001 |
| Elective | 0 | 7,864/17,730(45%) | 976/2,912(34%)) | <0.0001 |
| Left Ventricular Systolic Function |
| Good (LVEF >50%)  | 11,737(57%) | 4,202/7,414(57%) | 731/1,491(49%) | <0.0001 |
|  Moderate (LVEF 30-50%)  | 11,737(57%) | 2,516/7,414(34%) | 582/1,491(39%) |
|  Poor (LVEF <30%) | 11,737(57%) | 696/7,414(9%) | 178/1,491(12%) |
| Access site (AS) |
|  Femoral  | 0 | 11,600/17,730(65%) | 2,083/2,912(71%) | <0.0001 |
|  Radial  | 0 | 5,666/17,730(32%) | 860/2,912(29%) | 0.009 |
|  |
| Glycoprotein IIb/IIIa inhibitor  | 1,065(5%) | 3,572/16,973(21%) | 762/2,604(29%) | <0.0001 |
| Cardiogenic shock  | 225(1%) | 225/17,529(1.28%) | 19/2,888(0.66%) | 0.004 |
| Circulatory support  | 497(2%) | 310/17,475(1.77%) | 44/2,670(1.65%) | 0.64 |
| DES use  | 768(4%) | 11,533/17,099(67%) | 1,840/2,775(66%) | 0.23 |
|  | Number of stents |
| 0  | 275(1%) | 1,793/17,483(10%) | 56/2,884(2%) | <0.0001 |
| 1  | 275(1%) | 8,987/17,483(51%) | 1,567/2,884(54%) |
| 2  | 275(1%) | 4,095/17,483(24%) | 767/2,884(27%) |
| ≥3  | 275(1%) | 2,608/17,483(15%) | 494/2,884(17%) |
| Thrombus aspiration  | 235(1%) | 1,390/17,683(8%) | 347/2,724(13%) | <0.0001 |
| Mechanical ventilator support  | 3,263(16%) | 279/14,875(2%) | 22/2,504(1%) | <0.0001 |
| Median follow up period in years (IQR) | 0 | 4.18 (2.08 – 6.74) | 3.73(2.07 – 5.65) | <0.0001 |
| Procedural complications |  |  |  |  |
| Dissection | 966(5%) | 151/17,076(0.88%) | 25/2,600(0.96%) | 0.70 |
| Perforation | 966(5%) | 77/17,076(0.45%) | 16/2600(0.62%) | 0.26 |
| Any procedural complications\* | 966(5%) | 800/17,076(4.68%) | 201/2,600(7.73%) | <0.0001 |

PCI; Percutaneous Coronary Intervention, EPD; Embolic protection devices, IQR; Interquartile range, MI; Myocardial Infarction, CVA; Cerebrovascular accident, STEMI; ST segment elevation Myocardial Infarction, NSTEMI; Non-ST segment elevation Myocardial Infarction, UA; Unstable angina, LVEF; Left Ventricular ejection fraction, DES; Drug eluted stent

\* Any procedural complication includes Aortic dissection, Coronary perforation, Heart block requiring pacing, DC cardioversion, no flow/slow flow phenomenon, need ventilation, Shock induced by procedure